Karyopharm Therapeutics Inc.

Listed Company

KPTICIK 0001503802NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$146.07M

Net Income

$-196.04M

Total Assets

$108.42M

Equity

$-292.93M

Shares Out

22.66M

Op. Cash Flow

$-75.37M

KPTI$9.51+132.11% · past yearDBEQ Basic

Daily closing prices

Business

Karyopharm Therapeutics is a commercial-stage pharmaceutical company developing and commercializing first-in-class drugs targeting nuclear export protein XPO1 for cancer treatment. The company's lead asset, XPOVIO (selinexor), is an oral XPO1 inhibitor approved in the U.S. for multiple myeloma and diffuse large B-cell lymphoma, and marketed internationally under the brand name NEXPOVIO through licensed partners. The company is advancing selinexor through late-stage clinical trials in myelofibrosis, endometrial cancer, and additional multiple myeloma indications, and developing next-generation XPO1 inhibitor eltanexor.

Summary from 10-K filed 2026-02-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue from contract with customer, license and other revenue	146	145	146	157	210
Research and development	126	143	139	149	161
Selling, general and administrative	105	115	132	145	144
Total operating expenses	237	265	276	299	308
Loss from operations	−91	−119	−130	−142	−98
Interest income	3	7	11	2	582,000
Interest expense	−46	−37	−24	−25	—
(Loss) gain on extinguishment of debt	−62	45	0	0	—
Other income (expense), net	152,000	28	−356,000	−83,000	−85,000
Total other (expense) income, net	−105	43	−13	−23	−26
Loss before income taxes	−196	−76	−143	−165	−124
Income tax provision	−43,000	−57,000	−300,000	−400,000	−300,000
Net loss	−196	−76	−143	−165	−124
Basic net loss per share	−17.93	−9.41	−18.79	−2.02	−1.65
Diluted net loss per share (Note 2)	−17.93	−14	−18.79	−2.02	−1.65
Weighted-average number of common shares outstanding used to compute basic net loss per share	10,935	8,125	7,616	81,871	75
Weighted-average number of common shares outstanding used to compute diluted net loss per share	10,935	8,455	7,616	81,871	75

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	61	62	52	135	190
Investments	3	46	139	143	38
Accounts receivable, net	26	31	27	47	22
Inventory	4	5	3	4	4
Prepaid expenses and other current assets	9	12	12	20	14
Total current assets	103	156	234	350	276
Property and equipment, net	104,000	400,000	606,000	1	2
Operating lease right-of-use assets	5	6	4	6	8
Restricted cash	351,000	338,000	301,000	633,000	637,000
Other assets	267,000	1	1	0	20
Total assets	108	164	240	358	305
Accounts payable	4	5	3	3	2
Accrued expenses	64	61	61	58	69
Convertible senior notes due 2025	0	24	0	—	—
Senior secured term loan	21	0	—	—	—
Operating lease liabilities	969,000	438,000	3	3	2
Other current liabilities	2	2	2	2	678,000
Total current liabilities	92	92	69	66	74
Convertible senior notes due 2029	90	68	0	—	—
Convertible senior notes due 2028	21	0	—	—	—
Senior secured term loan, net of current portion	95	95	0	—	—
Deferred royalty obligation	72	73	132	133	133
Common stock warrants	14	13	0	—	—
Operating lease liabilities, net of current portion	6	7	3	6	9
Other liabilities	11	2	978,000	0	—
Total liabilities	401	350	377	375	385
Preferred stock, $0.0001 par value; 5,000 shares authorized; none issued and outstanding	0	0	0	0	0
Common stock, $0.0001 par value; 53,333 shares authorized; 18,311 and 8,413 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	14,000	13,000	12,000	12,000	8,000
Additional paid-in capital	1,466	1,378	1,351	1,328	1,099
Accumulated other comprehensive income (loss)	71,000	−356,000	−161,000	−638,000	191,000
Accumulated deficit	−1,800	−1,563	−1,487	−1,344	−1,179
Total stockholders' deficit	−293	−186	−136	−17	−80
Total liabilities and stockholders' deficit	108	164	240	358	305

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−196	−76	−143	−165	−124
Stock-based compensation expense	14	18	22	35	30
Depreciation and amortization	296,000	340,000	530,000	621,000	789,000
Amortization of debt issuance costs and discounts	11	6	814,000	812,000	780,000
Interest expense added to debt principal	6	0	0	—	—
Net amortization of premiums and discounts on investments	−410,000	−3	−4	−825,000	2
Change in fair value of embedded derivatives and common stock warrants	−707,000	−29	0	−281,000	−100,000
Accounts receivable, net	5	−4	20	−5	−10
Inventory	701,000	−2	1	−118,000	−1
Prepaid expenses and other assets	4	−432,000	7	−6	−25
Operating lease right-of-use assets	1	−2	2	2	1
Accounts payable	−1	2	350,000	1	−3
Accrued expenses and other liabilities	19	4	4	−10	16
Operating lease liabilities	−438,000	1	−3	−2	−2
Net cash used in operating activities	−75	−127	−93	−150	−107
Proceeds from maturities of investments	43	154	167	122	193
Purchases of investments	0	−59	−159	−226	−45
Purchases of property and equipment	0	−142,000	0	−118,000	−212,000
Net cash provided by investing activities	43	95	8	−104	142
Proceeds from convertible debt	15	0	0	—	—
Proceeds from senior secured term loan	12	83	0	0	—
Proceeds from issuance of common stock and warrants in private placement offering	9	0	0	—	—
Proceeds from the exercise of stock options and shares issued under the employee stock purchase plan	761,000	1	1	4	4
Payment of convertible debt	−250,000	0	0	—	—
Payment of deferred royalty obligation	0	−41	0	0	—
Payment of debt and equity issuance costs	−6	−3	0	—	—
Net cash provided by financing activities	30	42	1	194	74
Effect of exchange rates on cash, cash equivalents and restricted cash	20,000	−11,000	−34,000	−488,000	−48,000
Net (decrease) increase in cash, cash equivalents and restricted cash	−2	10	−84	−61	108
Cash paid for interest on deferred royalty obligation	4	21	16	29	10
Cash paid for interest on convertible debt and term loan	11	17	5	5	5
Cash paid for amounts included in the measurement of operating lease liabilities	1	3	4	3	3
Lease liabilities arising from obtaining right-of-use assets	0	4	0	0	—
Debt issued for interest payments	13	0	0	—	—
Convertible senior notes due 2029 issued with warrants to purchase 3,100 shares of common stock in exchange for a $148,000 reduction of convertible senior notes due 2025	0	111	0	0	—
Senior secured term loan issued in exchange for a $14,700 reduction of deferred royalty obligation	0	15	0	0	—
Issuance of common stock and warrants used to settle fees related to financing activities	0	8	0	0	—
Convertible senior notes due 2029 issued in exchange for a $5,000 reduction of deferred royalty obligation	0	5	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Karyopharm Therapeutics Inc.'s CIK number?

Karyopharm Therapeutics Inc.'s SEC CIK number is 0001503802 (1503802). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Karyopharm Therapeutics Inc.'s SEC filings?

All of Karyopharm Therapeutics Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Karyopharm Therapeutics Inc. last report earnings?

Karyopharm Therapeutics Inc. (KPTI) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-222808). This is Karyopharm Therapeutics Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Karyopharm Therapeutics Inc.'s most recent earnings 8-K?

Karyopharm Therapeutics Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-222808. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Karyopharm Therapeutics Inc.'s latest earnings 8-K →
Look up any company's CIK number →